Literature DB >> 22718259

[Hemorrhagic disorders].

B Kemkes-Matthes1, K Heidinger, A Kirsch-Altena, R Fischer.   

Abstract

Patients suffering from hemorrhagic disorders often present with only minimal bleeding during surgery or injuries. However, some patients have life-threatening bleeding. Simple screening tests can be used to find the cause of the bleeding: patient and family histories provide information on whether the bleeding tendency is hereditary or acquired. Clinical examination can reveal the bleeding type. Measurement of platelet count can be used to exclude thrombocytopenia. Coagulation tests, such as prothrombin time (PT, Quick) and activated partial thromboplastin time (aPTT) can supply initial information concerning deficiency states of coagulation factors. Bleeding time is often prolonged in patients suffering from von Willebrand disease, thrombocytopenia or thrombocytopathy. If--due to the results of these screening tests-further testing of particular coagulation factors or platelet function is needed, then patients should be referred to a centre specialized in blood coagulation.

Entities:  

Mesh:

Year:  2012        PMID: 22718259     DOI: 10.1007/s00108-012-3034-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  7 in total

Review 1.  Surgery and inhibitor development in hemophilia A: a systematic review.

Authors:  C L Eckhardt; J G van der Bom; M van der Naald; M Peters; P W Kamphuisen; K Fijnvandraat
Journal:  J Thromb Haemost       Date:  2011-10       Impact factor: 5.824

Review 2.  Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.

Authors:  S Dupuis-Girod; S Bailly; H Plauchu
Journal:  J Thromb Haemost       Date:  2010-03-19       Impact factor: 5.824

Review 3.  Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

Authors:  J Astermark; C Altisent; A Batorova; M J Diniz; A Gringeri; P A Holme; A Karafoulidou; M F Lopez-Fernández; B M Reipert; A Rocino; M Schiavoni; M von Depka; J Windyga; K Fijnvandraat
Journal:  Haemophilia       Date:  2010-04-14       Impact factor: 4.287

Review 4.  Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.

Authors:  E Berntorp; J Astermark; F Baghaei; D Bergqvist; M Holmström; B Ljungberg; A Norlund; J Palmblad; P Petrini; L Stigendal; J Säwe
Journal:  Haemophilia       Date:  2011-12-12       Impact factor: 4.287

Review 5.  A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.

Authors:  C Knight; A M Danø; T Kennedy-Martin
Journal:  Haemophilia       Date:  2009-02-01       Impact factor: 4.287

6.  New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.

Authors:  K Kurnik; C Bidlingmaier; W Engl; H Chehadeh; B Reipert; G Auerswald
Journal:  Haemophilia       Date:  2009-10-29       Impact factor: 4.287

Review 7.  Hereditary haemorrhagic telangiectasia: a clinical and scientific review.

Authors:  Fatima S Govani; Claire L Shovlin
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.